← stocks-llm Find companies like MRNA →

Moderna (MRNA)

Health Care · mRNA therapeutics and vaccines

Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and declining sales.

What Moderna does

Moderna develops and commercializes mRNA-based vaccines and therapeutics for infectious diseases, oncology, and rare diseases. The company manufactures its mRNA products at its own facilities and through third-party partners. Following a significant decline from COVID-19 peak revenues, Moderna is focused on advancing its clinical pipeline and establishing market acceptance for next-generation vaccines and cellular therapies, while managing its cost structure as it transitions from pandemic-driven sales.

Themes: ["mRNA platform","vaccine development","oncology/cancer immunotherapy","personalized medicine","infectious disease vaccines","clinical stage programs","manufacturing scale-up"]

Fundamentals

Ask why MRNA looks like this →

Key risks (from latest filing)

["Steep revenue decline of -30% YoY and persistent unprofitability with -144% net margin, reliant on limited revenue base from legacy COVID vaccines and early-stage product launches","Intense competitive vaccine market and execution risk on late-stage pipeline programs, with regulatory approval uncertainty and clinical trial delays potentially impacting commercialization timeline","Manufacturing complexity and supply chain dependencies, particularly for personalized therapies like intismeran autogene which require single-patient custom production processes and novel manufacturing approaches"]

See MRNA's biggest risks from its latest 10-Q →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.